Q2 2026 Teleflex Inc Earnings Call Transcript

Aug 6, 2026 / 12:00 PM GMT

Release Date Price: €115.3

Transcript 10-Q8-K

Key Points

Positve

Teleflex Inc (TFX) delivered better-than-expected revenue, adjusted margins, and adjusted EPS in Q2 2026, with strong performance in vascular and surgical businesses.
The company successfully closed the OEM divestiture, generating approximately $1.5 billion in proceeds, which will fund debt reduction and share repurchases.
Teleflex Inc (TFX) is committed to returning capital to shareholders, having completed a $250 million share repurchase in Q2 and announcing an additional $250 million ASR to commence on August 7, 2026.
The company received FDA approval for EasyPlas, a freeze-dried plasma product, expanding its emergency medicine portfolio and addressing an unmet need in pre-hospital and combat settings.
Teleflex Inc (TFX) achieved significant clinical milestones for its FreeSol drug-eluting resorbable magnesium scaffold, including completing patient enrollment in the BioMag 2 trial ahead of schedule and commencing the US pivotal BioMag 3 trial.
The company raised its adjusted EPS guidance for 2026 to $6.90-$7.20, reflecting the benefit of share repurchases and lower net interest expense.
Teleflex Inc (TFX) is on track with its restructuring plan, expected to achieve approximately $50 million in annual pre-tax cost savings by mid-2028, and is actively mitigating stranded costs from divestitures.
The company's adjusted tax rate improved to 9.9% in Q2, benefiting from the One Big Beautiful Bill Act and favorable jurisdictional mix.
Teleflex Inc (TFX) expects a significant step-up in financial performance in 2027, with improved adjusted margins and EPS, driven by divestiture proceeds, cost savings, and lower interest expense.
The company's new CEO, Jason Weidman, brings 20 years of interventional experience and expresses strong conviction in the long-term prospects of the interventional business.

Negative

Teleflex Inc (TFX) reduced its 2026 pro forma adjusted constant currency revenue growth guidance to 3.5%-4.5% from 4.5%-5.5%, primarily due to slower-than-expected integration of the vascular intervention (VI) business.
Interventional revenue decreased 1% in Q2, falling short of expectations due to ongoing integration and restructuring activities, including order-to-cash transitions, distributor changes, and sales force realignment.
The integration of the VI business is taking longer than anticipated, with the timeline extended through the second half of 2026, and the company expects a gradual ramp-up in sales force productivity.
Adjusted gross margin decreased 80 basis points year-over-year in Q2, impacted by tariffs and the addition of the lower-margin VI business.
Adjusted operating margin declined 520 basis points year-over-year to 19.6%, reflecting gross margin pressure, higher operating expenses from the VI business, and increased R&D investment.
The company did not receive any IEPA tariff refunds in Q2, and its 2026 guidance does not include any benefit from potential refunds, which could impact earnings if not realized.
The acute care and interventional urology divestiture is still pending FTC approval, with a second request issued in March, and the closing is anticipated in Q4 2026, subject to regulatory timing.
Teleflex Inc (TFX) faces potential headwinds in vascular and surgical growth in the second half of 2026, as distributor inventories have crept up and surgical comps become more difficult.
The company's leverage ratio increased to approximately 2.8 times at the end of Q2, up slightly from Q1, due to borrowings for share repurchases.
The new CEO's strategic review is ongoing, and the company has not yet provided a long-term plan, leaving uncertainty about future capital allocation and growth strategy.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TFX.N - Teleflex Incorporated
Q2 2026 Teleflex Inc Earnings Call
Aug 06, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by.

Good morning ladies and gentlemen, and welcome to the Teleflex second quarter 2026 earnings conference call.

This time all participants have been placed in a listen-only mode.

At the end of the company's prepared remarks, we will conduct a question-and-answer session.

Please note that this conference call is being recorded and will be available on the company's website for replay shortly.

And now we'll turn the call over to Kirsch, Vice President of Investor Relations and strategy development, please go ahead.

Good morning everyone and welcome to the Teleplex Incorporated second quarter 2026 earnings conference call.

The press release and slides to accompany

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.